학술논문

Preclinical Metrics Correlate With Drug Activity in Phase II Trials of Targeted Therapies for Non-Small Cell Lung Cancer.
Document Type
Article
Source
Frontiers in Oncology; 11/5/2020, Vol. 11, pN.PAG-N.PAG, 11p
Subject
CRIZOTINIB
NON-small-cell lung carcinoma
CLINICAL drug trials
CELLULAR therapy
Language
ISSN
2234943X
Abstract
Copyright of Frontiers in Oncology is the property of Frontiers Media S.A. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)